TriangleDanvatirsen (NCT05986240)
Danvatirsen trial for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05986240). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for relapsed or refractory acute myeloid leukemia, or higher risk myelodysplastic syndrome, in adults.
The idea: block a protein called STAT3. Danvatirsen is an antisense drug that targets STAT3. Patients first receive it alone, then together with venetoclax, in dose escalation groups. Venetoclax blocks BCL-2, a protein found on some cancer cells.
This phase 1 study looks at safety and response, and plans 38 patients. At Montefiore Medical Center in the Bronx, New York, Aditi Shastri leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.